equityflowunderstand the flow and follow it
EquityFlow › Companies › SynOx Therapeutics

SynOx Therapeutics

Biotech · Dublin, IE

Dublin/Oxford biopharma developing emactuzumab for tenosynovial giant cell tumour.

In the network

Shares the most investors with (number = shared investors):
Precirix 2

Funding history

DateRoundAmount
Apr 2024Series B
SynOx Therapeutics secured $75m in Series B financing co-led by Forbion, HealthCap and Bioqube Ventures to run a phase 3 trial of emactuzumab for TGCT.
$75M

Investors

Tap an investor to see what else they have backed.

Bioqube VenturesForbionHealthCap

Other companies in Biotech

ImperagenHaga BiosciencePixelgen TechnologiesGallantChai DiscoverySNIPR BiomeCellbox LabsScope BiosciencesGenLuminaActitheraNUCLIDIUMAnocca

Other companies in IE

CameraMaticsFonoaSports Impact TechnologiesAntler BioFloVision SolutionsAerskaDeciphexMeta-FluxNorySeapointRekordPower Capital

Other companies at Series B stage

0x Labs11x.ai1K Kirana1X Technologies1plusX3Commas3SC4baseCare4screen8fig9finACALL
Explore funding flow on EquityFlow →

Data is community-curated and may be incomplete.